ABI-007 and Bevacizumab in Treating Women With Recurrent or Metastatic Breast Cancer

DISEASE CHARACTERISTICS: * Histologically or cytologically confirmed invasive breast cancer * Recurrent or metastatic disease OR locally recurrent disease not amenable to resection with curative intent * Measurable or nonmeasurable disease * No CNS metastases by CT scan or MRI * No HER2-neu-positive tumors * Hormone receptor status not specified PATIENT CHARACTERISTICS: * Female * Menopausal status not specified * Performance status 0-1 * Absolute neutrophil count ≥ 1,500/mm³ * Platelet count \> 100,000/mm³ * Creatinine \< 2.0 mg/dL * Bilirubin normal * AST ≤ 2 times upper limit of normal (ULN) (5 times ULN if there is known liver involvement) * Urine protein:creatinine ratio \< 1.0 OR proteinuria \< 2+ by urine dipstick OR ≤ 1 g protein on 24-hour urine collection * No peripheral neuropathy \> grade 1 * Not pregnant or nursing * Negative pregnancy test * Fertile patients must use effective contraception * No other malignancies within the past 5 years except carcinoma in situ of the cervix, melanoma in situ, or basal cell carcinoma of the skin * No inadequately controlled hypertension, defined as systolic blood pressure (BP) \> 150 mm Hg and/or diastolic BP \> 100 mm Hg on antihypertensive medications * No prior hypertensive crisis or hypertensive encephalopathy * No New York Heart Association class II-IV congestive heart failure * No myocardial infarction or unstable angina within the past 6 months * No stroke or transient ischemic attack within the past 6 months * No significant vascular disease (e.g., aortic aneurysm or aortic dissection) * No symptomatic peripheral vascular disease * No evidence of bleeding diathesis or coagulopathy * No significant traumatic injury within the past 28 days * No abdominal fistula, gastrointestinal perforation, or intra-abdominal abscess within the past 6 months * No serious, nonhealing wound, ulcer, or bone fracture * No known hypersensitivity to any component of bevacizumab PRIOR CONCURRENT THERAPY: * No prior paclitaxel albumin-stabilized nanoparticle formulation (ABI-007; Abraxane\^®) or bevacizumab * No prior chemotherapy for metastatic disease * Prior hormonal therapy for metastatic disease allowed * At least 4 weeks since any prior therapy for cancer * More than 12 months since prior adjuvant chemotherapy, including use of a taxane * More than 28 days since prior major surgery or open biopsy * More than 7 days since prior core biopsy or minor surgery (excluding placement of a vascular access device) * No concurrent major surgery * No other concurrent therapy for breast cancer * Concurrent bisphosphonates allowed if there is bone involvement * No concurrent prophylactic granulocyte colony-stimulating factors